INDVNasdaqPharmaceutical PreparationsFiscal year ends December 31

Indivior Pharmaceuticals, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026

$33.87+1.42 (+4.38%)

Close on Oct 19, 2026

Market cap: $4.20B
P/E (TTM): 12.2
Dividend yield: –

Indivior Pharmaceuticals, Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Cash & Equivalents	195	319	316	774	1,102	858
Short-Term Investments	0	1.00	94	–	–	–
Cash & Short-Term Investments	195	320	410	774	1,102	858
Receivables	253	254	254	220	202	–
Inventory	153	167	126	114	95	–
Prepaid Expenses & Other	34	31	52	–	–	–
Other Current Assets	16	21	457	27	32	–
Total Current Assets	652	827	1,257	1,259	1,444	–
Property, Plant & Equipment	144	100	84	54	58	–
Gross Property, Plant & Equipment	251	190	165	–	–	–
Accumulated Depreciation	-107	-90	-81	–	–	–
Long-Term Investments	28	27	41	–	–	–
Operating Lease Right-of-Use Assets	26	39	40	31	37	43
Goodwill	2.00	2.00	5.00	–	–	–
Deferred Tax Assets	323	277	286	219	105	–
Other Long-Term Assets	27	39	36	38	106	–
Total Assets	1,201	1,316	1,758	1,769	1,832	–
Accounts Payable	48	63	195	617	720	–
Short-Term Debt	–	–	3.00	3.00	3.00	–
Current Portion of Long-Term Debt	29	18	3.00	–	–	–
Current Debt	29	18	6.00	3.00	3.00	–
Current Portion of Leases	10	10	9.00	8.00	8.00	–
Current Income Taxes Payable	2.00	7.00	8.00	9.00	7.00	–
Other Current Liabilities	0	11	40	79	61	–
Total Current Liabilities	914	924	1,281	1,019	804	–
Long-Term Debt	290	315	237	237	239	–
Long-Term Leases	22	32	34	29	36	–
Operating Lease Liabilities	32	42	43	37	44	–
Other Long-Term Liabilities	21	18	31	428	474	–
Total Liabilities	1,300	1,652	1,942	1,718	1,629	–
Total Debt	319	333	243	240	242	–
Common Stock	62	62	68	68	70	–
Additional Paid-In Capital	112	90	88	8.00	7.00	–
Retained Earnings	-243	-443	-288	1,303	1,438	–
Comprehensive Income & Other	-30	-36	-30	–	–	–
Shareholders' Equity	-98	-337	-184	-15	121	–
Total Equity	-98	-337	-184	-15	121	82
Total Liabilities & Equity	1,201	1,316	1,758	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 82.1%
Operating margin: 31.6%
Net margin: 26.7%
Return on equity, FY2025: -96.6%

Financial strength

Current ratio: 0.84
Debt to equity: -2.34
Debt to assets: 39.5%
Cash to current liabilities: 25.6%

Valuation

P/E ratio: 12.2
Price to sales: 3.15
Price to book: –
Dividend yield: –